Blood Cancer Talks

In this episode, we delve into the history of frontline treatment in young/fit patients with Hodgkin's lymphoma and recent developments in the past decade with Dr. Nancy Bartlett from Washington University.

Link for our Blood Cancer Talks Survey:

Here are the key trials we discussed:

1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):
2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):
3. ECHELON-1 (Replacing Bleomycin by Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma):
4. BREACH (BV-AVD vs ABVD for Early Stage Unfavorable Hodgkin’s Lymphoma):
5. S1826 (Nivo-AVD vs BV-AVD in Advanced Hodgkin’s Lymphoma):
6. FIL-ROUGE (PET-adapted ABVD vs Dose-Intensified ABVD):
7.  HD21 (BRECADD vs EBEACOPP in Advanced Hodgkin’s Lymphoma):

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk